Trevicta 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
WS/2405 
This was an application for a variation following a 
25/05/2023 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
amended 
on 
SmPC, 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
data 
IG/1499 
C.I.11.a - Introduction of, or change(s) to, the 
21/03/2022 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
wording agreed by the competent authority 
PSUSA/2266/
Periodic Safety Update EU Single assessment - 
10/02/2022 
n/a 
PRAC Recommendation - maintenance 
202106 
paliperidone 
IB/0028 
B.II.d.2.d - Change in test procedure for the finished 
08/11/2021 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
WS/1877 
This was an application for a variation following a 
09/04/2021 
29/04/2022 
SmPC and PL 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IG/1257 
C.I.11.a - Introduction of, or change(s) to, the 
21/07/2020 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
wording agreed by the competent authority 
WS/1833/G 
This was an application for a group of variations 
25/06/2020 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
Page 2/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.b.z - Change in control of the AS - Other 
variation 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
R/0022 
Renewal of the marketing authorisation. 
19/09/2019 
14/11/2019 
SmPC 
WS/1638 
This was an application for a variation following a 
11/07/2019 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.c.z - Container closure system of the AS - Other 
variation 
IB/0019/G 
This was an application for a group of variations. 
07/03/2019 
n/a 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
IB/0016/G 
This was an application for a group of variations. 
07/03/2019 
n/a 
B.I.z - Quality change - Active substance - Other 
variation 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
Page 3/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IG/1075/G 
This was an application for a group of variations. 
28/02/2019 
n/a 
B.I.b.2.c - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure for a reagent, which 
does not have a significant effect on the overall 
quality of the AS 
B.III.2.b - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
to comply with an update of the relevant monograph 
of the Ph. Eur. or national pharmacopoeia of a 
Member State 
IA/0020/G 
This was an application for a group of variations. 
27/02/2019 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
PSUSA/2266/
Periodic Safety Update EU Single assessment - 
14/02/2019 
n/a 
PRAC Recommendation - maintenance 
201806 
paliperidone 
IA/0018/G 
This was an application for a group of variations. 
06/02/2019 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
Page 4/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IA/0017 
B.I.b.1.d - Change in the specification parameters 
06/02/2019 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
WS/1417/G 
This was an application for a group of variations 
13/09/2018 
12/12/2018 
SmPC, 
Caution is warranted in patients receiving both, 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
Update of sections 4.4 and 4.5 of the SmPC in order 
to add information regarding concomitant use of 
paliperidone and risperidone with psychostimulants 
(in line with the CMDh recommendations for 
risperidone) and of section 4.8 of the SmPC to add 
catatonia as a new side-effect categorised as ‘Rare’. 
The Package Leaflet is updated accordingly. The MAH 
took also the occasion to include editorial changes in 
the PI and to update the local representative for 
Ireland in the Package leaflet for Trevicta, Invega 
and Xeplion and Bulgaria for Risperidal Consta. The 
Labelling and 
psychostimulants (e.g., methylphenidate) and paliperidone 
PL 
concomitantly, as extrapyramidal symptoms could emerge 
when adjusting one or both medications. Gradual 
withdrawal of stimulant treatment is recommended.  
Catatonia has been introduced in the list of adverse drug 
reaction with a rare frequency. 
Page 5/10 
 
 
 
 
 
 
 
 
 
 
MAH also implemented the weekdays in section 5 of 
the annex IIIA for invega OPA blister according to 
the QRD guidance. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
WS/1359 
This was an application for a variation following a 
31/05/2018 
12/12/2018 
SmPC and PL 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Update of section 4.8 of the SmPC in order to include 
somnambulism and sleep-related eating disorder 
under a rare and not known frequency, respectively, 
after post marketing reports analysis. The Package 
Leaflet is updated accordingly. In addition, for 
INVEGA/XEPLION/TREVICTA minor editorial changes 
have been introduced and the details of the local 
representatives in Portugal, Belgium Iceland, 
Slovenia, Netherlands and Luxembourg are updated 
in the Package Leaflet. An update is also proposed to 
the INVEGA Package Leaflet in section 2 to add a 
standard statement concerning sodium content 
according to the Annex to the European Commission 
guideline on 'Excipients in the labelling and package 
leaflet of medicinal products for human use’. 
Updated wording to align to the Excipients Guideline 
Page 6/10 
 
 
 
 
 
 
 
 
 
is also proposed for Risperdal Oral, together with 
removing the brand name (West Medimop) for the 
vial adaptors for Risperdal Consta. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
II/0011 
Update of section 4.8 of the SmPC in order to update 
14/09/2017 
12/12/2018 
SmPC and PL 
There were no new adverse drug reactions following the 
the safety information after assessment of study 
R092670-SCA-3004 (A Randomized, Double-Blind, 
Placebo-Controlled, Parallel-Group Study of 
Paliperidone Palmitate Evaluating Time to Relapse in 
Subjects With Schizoaffective Disorder). The Package 
Leaflet has been updated accordingly. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
assessment of study R092670-SCA-3004; only changes to 
frequencies of existing ADRs have been identified. For more 
information please refer to the Summary of Product 
Characteristics. 
IB/0009 
C.I.z - Changes (Safety/Efficacy) of Human and 
17/09/2016 
14/09/2017 
SmPC 
Veterinary Medicinal Products - Other variation 
X/0007/G 
This was an application for a group of variations. 
01/04/2016 
26/05/2016 
SmPC, Annex 
Please refer to Scientific Discussion Trevicta-H-4066-X-
Annex I_2.(c) Change or addition of a new 
strength/potency 
A.2.a - Administrative change - Change in the 
(invented) name of the medicinal product for CAPs 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
II, Labelling 
0007-G-AR. 
and PL 
Page 7/10 
 
 
 
 
 
 
 
 
 
 
 
 
modification of an approved one 
C.I.7.b - Deletion of - a strength 
C.I.7.b - Deletion of - a strength 
C.I.7.b - Deletion of - a strength 
C.I.7.b - Deletion of - a strength 
C.I.7.b - Deletion of - a strength 
C.I.7.b - Deletion of - a strength 
PSUSA/2266/
Periodic Safety Update EU Single assessment - 
14/01/2016 
n/a 
PRAC Recommendation - maintenance 
201506 
paliperidone 
WS/0760 
This was an application for a variation following a 
16/07/2015 
13/04/2016 
SmPC and PL 
Anaphylactic reactions in patients who have previously 
tolerated oral risperidone or oral paliperidone have been 
rarely reported during post marketing experience. 
If hypersensitivity reactions occur, discontinue use of 
paliperidone; initiate general supportive measures as 
clinically appropriate and monitor the patient until signs 
and symptoms resolve. 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Update of sections 4.4 and 4.8 of the SmPC in order 
to add a warning and update the safety information 
based on post-marketing experience on occurrence 
of hypersensitivity reactions in patients who have 
previously tolerated oral risperidone or paliperidone. 
The Package Leaflet is updated accordingly. 
In addition, the Worksharing applicant (WSA) took 
the opportunity to introduce minor editorial changes 
and to update the list of local representatives for 
Belgium and Luxemburg in the Package Leaflet. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IG/0582/G 
This was an application for a group of variations. 
01/07/2015 
n/a 
Page 8/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.11.a - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
wording agreed by the competent authority 
C.I.11.a - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
wording agreed by the competent authority 
WS/0700 
This was an application for a variation following a 
25/06/2015 
13/04/2016 
SmPC and PL 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IG/0549 
C.I.11.a - Introduction of, or change(s) to, the 
29/04/2015 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
wording agreed by the competent authority 
IB/0003 
C.I.2.a - Change in the SPC, Labelling or PL of a 
27/04/2015 
13/04/2016 
SmPC 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IG/0531 
B.II.b.1.a - Replacement or addition of a 
05/03/2015 
n/a 
Page 9/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing site for the FP - Secondary packaging 
site 
Page 10/10 
 
 
 
 
 
 
 
